Cancer Letters 461 (2019) 155

Contents lists available at ScienceDirect

Cancer Letters

journal homepage: www.elsevier.com/locate/canlet

Corrigendum

Corrigendum to "The dual specificity PI3K/mTOR inhibitor PKI-587 displays efficacy against T-cell acute lymphoblastic leukemia (T-ALL)" [Cancer Lett. 392 (1) (2017) 9–16]

Mohiuddin Gazi[a,b], Sausan A. Moharram[a,b], Alissa Marhäll[a,b], Julhash U. Kazi[a,b,*]

[a] Division of Translational Cancer Research, Department of Laboratory Medicine, Lund University, Lund, Sweden
[b] Lund Stem Cell Center, Department of Laboratory Medicine, Lund University, Lund, Sweden

The authors regret that incorrect images appear in Fig. 7. The first author (M. Gazi) was solely responsible for the incorrect images. Unfortunately, pp38 image from the right panel was duplicated in the left (S6K) panel of Fig. 7A and loading controls appeared from different blots. Authors apologize for the mistakes and provide corrected blots.

In the corrected figure, AKT, pAKT, ERK2 and pERK1/2 images were from the same blot whereas the S6K, pS6K, p38 and pp38 images were from another blot. However, both blots were from the same experiment and the same lysates were used. Additionally, cm^3 in the Y-axis of Fig. 6A of original article should be read as mm^3.

This correction does not change the conclusions of the manuscript. The authors would like to apologize for any inconvenience caused.



Fig. 7. PKI-587 selectively inhibits AKT and S6K phosphorylation: (A) Cells were treated with increasing concentrations of PKI-587 before lysis. Cell lysates were used to assess the phosphorylation of signaling proteins using phospho-specific antibodies. In the previous incorrect figure, several phospho-protein images were obtained from different blots. Only one loading control was used although images were taken from the different blots and loading control was mislabeled (it should be Beta-Actin instead of Tubulin). In the corrected figure, lysates from the same experiment were used to run two SDS-PAGEs. One blot was probed with anti-phospho-AKT, anti-phospho-ERK1/2, anti-AKT and anti-ERK2 antibodies (Beta-actin used as a loading control) and another blot was probed with anti-phospho-S6K, anti-phospho-p38, anti-S6K and anti-p38 antibodies (Beta-actin used as a loading control). (B) Tumors from mice treated with either PKI-587 or vehicle were used to assess the phosphorylation of signaling proteins using phospho-specific antibodies. Similar to figure A, incorrect loading controls were used previously and now have been corrected similarly as described in figure A.

DOI of original article: https://doi.org/10.1016/j.canlet.2017.01.035
* Corresponding author. Division of Translational Cancer Research, Department of Laboratory Medicine, Lund University, Lund, Sweden.
E-mail address: kazi.uddin@med.lu.se (J.U. Kazi).

https://doi.org/10.1016/j.canlet.2019.05.012